Abstract
Deficient vascularization is one of the prominent shortcomings of porous tissue-engineering scaffolds, which results in insufficient oxygen and nutrients transportation. Here, heparin cross-linked demineralized bone matrices (HC-DBM) pre-loaded with vascular endothelial growth factor (VEGF) were designed to promote cells and new microvessels invasion into the matrices. After being chemical crosslinked with heparin by N-hydroxysuccinimide and N-(3-di-methylaminopropyl)-N’-ethylcarbodiimide, the scaffold could bind more VEGF than the non-crosslinked one and achieve localized and sustained delivery. The biological activity of VEGF binding on heparinized collagen was demonstrated by promoting endothelial cells proliferation. Evaluation of the angiogenic potential of heparinized DBM loaded with VEGF was further investigated by subcutaneous implantation. Improved angiogenesis of heparinized DBM loaded with VEGF was observed from haematoxylin-eosin staining and immunohistochemistry examination. The results demonstrated that heparin cross-linked DBM binding VEGF could be a useful strategy to stimulate cells and blood vessels invasion into the scaffolds.
Similar content being viewed by others
References
Iwata H, Sakano S, Itoh T, Bauer TW. Demineralized bone matrix and native bone morphogenetic protein in orthopaedic surgery. Clin Orthop Relat Res. 2002;395(1):99–109.
Glowacki J, Kaban LB, Murray JE, Folkman J, Mulliken JB. Application of the biological principle of induced osteogenesis for craniofacial defects. Lancet. 1981;1(8227):959–62.
Trevisiol CH, Turner RT, Pfaff JE, Hunter JC, Menagh PJ, Hardin K, et al. Impaired osteoinduction in a rat model for chronic alcohol abuse. Bone. 2007;41(2):175–80.
Bomback DA, Grauer JN, Lugo R, Troiano N, Patel T, Friedlaender GE. Comparison of posterolateral lumbar fusion rates of Grafton Putty and OP-1 Putty in an athymic rat model. Spine. 2004;29(15):1612–7.
Morone MA, Boden SD. Experimental posterolateral lumbar spinal fusion with a demineralized bone matrix gel. Spine. 1998;23(2):159–67.
Martin GJ Jr, Boden SD, Titus L, Scarborough NL. New formulations of demineralized bone matrix as a more effective graft alternative in experimental posterolateral lumbar spine arthrodesis. Spine. 1999;24(7):637–45.
Rabie AB. Vascular endothelial growth pattern during demineralized bone matrix induced osteogenesis. Connect Tissue Res. 1997;36(4):337–45.
Zhao Y, Chen B, Lin H, Sun W, Zhao W, Zhang J, et al. The bone-derived collagen containing mineralized matrix for the loading of collagen-binding bone morphogenetic protein-2. J Biomed Mater Res. 2009;88:725–34.
Chen B, Lin H, Zhao Y, Wang B, Zhao Y, Liu Y, et al. Activation of demineralized bone matrix by genetically engineered human bone morphogenetic protein-2 with a collagen binding domain derived from von Willebrand factor propolypeptide. J Biomed Mater Res. 2007;80(2):428–34.
Lu M, Rabie AB. The effect of demineralized intramembranous bone matrix and basic fibroblast growth factor on the healing of allogeneic intramembranous bone grafts in the rabbit. Arch Oral Biol. 2002;47(12):831–41.
Wittbjer J, Palmer B, Rohlin M, Thorngren KG. Osteogenetic activity in composite grafts of demineralized compact bone and marrow. Clin Orthop Relat Res 1983;173(1):229–238.
Klagsbrun M, Moses MA. Molecular angiogenesis. Chem biol. 1999;6(8):R217–24.
Emad B, Sherifel M, Basma GM, Wong RW, Bendeus M, Rabie AB. Vascular endothelial growth factor augments the healing of demineralized bone matrix grafts. International journal of surgery(London, England). 2006;4(3):160–6.
van de Wijngaert FP, Tas MC, Burger EH. Characteristics of osteoclast precursor-like cells grown from mouse bone marrow. Bone Miner. 1987;3(2):111–23.
Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9(6):653–60.
Goth MI, Hubina E, Raptis S, Nagy GM, Toth BE. Physiological and pathological angiogenesis in the endocrine system. Microsc Res Tech. 2003;60(1):98–106.
Paku S, Paweletz N. First steps of tumor-related angiogenesis. Lab Invest. 1991;65(3):334–46.
Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–76.
Grunstein J, Masbad JJ, Hickey R, Giordano F, Johnson RS. Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature. Mol Cell Biol. 2000;20(19):7282–91.
Li J, Zhang YP, Kirsner RS. Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix. Microsc Res Tech. 2003;60(1):107–14.
Boontheekul T, Mooney DJ. Protein-based signaling systems in tissue engineering. Curr Opin Biotechnol. 2003;14(5):559–65.
Hao X, Silva EA, Mansson-Broberg A, Grinnemo KH, Siddiqui AJ, Dellgren G, et al. Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc Res. 2007;75(1):178–85.
van den Beucken JJ, Walboomers XF, Nillesen ST, Vos MR, Sommerdijk NA, van Kuppevelt TH, et al. In vitro and in vivo effects of deoxyribonucleic acid-based coatings funtionalized with vascular endothelial growth factor. Tissue Eng. 2007;13(4):711–20.
Rocha FG, Sundback CA, Krebs NJ, Leach JK, Mooney DJ, Ashley SW, et al. The effect of sustained delivery of vascular endothelial growth factor on angiogenesis in tissue-engineered intestine. Biomaterials. 2008;29(19):2884–90.
Chen RR, Silva EA, Yuen WW, Mooney DJ. Spatio-temporal VEGF and PDGF delivery patterns blood vessel formation and maturation. Pharm Res. 2007;24(2):258–64.
Sato M, Ishihara M, Ishihara M, Kaneshiro N, Mitani G, Nagai T, et al. Effects of growth factors on heparin-carrying polystyrene-coated atelocollagen scaffold for articular cartilage tissue engineering. J Biomed Mater Res B Appl Biomater. 2007;83(1):181–8.
Chung HJ, Kim HK, Yoon JJ, Park TG. Heparin immobilized porous PLGA microspheres for angiogenic growth factor delivery. Pharm Res. 2006;23(8):1835–41.
Wissink MJ, Beernink R, Poot AA, Engbers GH, Beugeling T, van Aken WG, et al. Improved endothelialization of vascular grafts by local release of growth factor from heparinized collagen matrices. J Control Release. 2000;64(1–3):103–14.
Gospodarowicz D, Cheng J. Heparin protects basic and acidic FGF from inactivation. J Cell Physiol. 1986;128(3):475–84.
Pike DB, Cai S, Pomraning KR, Firpo MA, Fisher RJ, Shu XZ, et al. Heparin-regulated release of growth factors in vitro and angiogenic response in vivo to implanted hyaluronan hydrogels containing VEGF and bFGF. Biomaterials. 2006;27(30):5242–51.
Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell. 1993;4(12):1317–26.
Lode A, Reinstorf A, Bernhardt A, Wolf-Brandstetter C, Konig U, Gelinsky M. Heparin modification of calcium phosphate bone cements for VEGF functionalization. J Biomed Mater Res. 2008;86(3):749–59.
Riley CM, Fuegy PW, Firpo MA, Shu XZ, Prestwich GD, Peattie RA. Stimulation of in vivo angiogenesis using dual growth factor-loaded crosslinked glycosaminoglycan hydrogels. Biomaterials. 2006;27(35):5935–43.
Steffens GC, Yao C, Prevel P, Markowicz M, Schenck P, Noah EM, et al. Modulation of angiogenic potential of collagen matrices by covalent incorporation of heparin and loading with vascular endothelial growth factor. Tissue Eng. 2004;10(9–10):1502–9.
Jeon O, Kang SW, Lim HW, Hyung Chung J, Kim BS. Long-term and zero-order release of basic fibroblast growth factor from heparin-conjugated poly(L-lactide-co-glycolide) nanospheres and fibrin gel. Biomaterials. 2006;27(8):1598–607.
Zhang J, Ding L, Zhao Y, Sun W, Chen B, Lin H, et al. Collagen-targeting vascular endothelial growth factor improves cardiac performance after myocardial infarction. Circulation. 2009;119(13):1776–84.
Yoon JJ, Chung HJ, Lee HJ, Park TG. Heparin-immobilized biodegradable scaffolds for local and sustained release of angiogenic growth factor. J Biomed Mater Res. 2006;79(4):934–42.
Rebai O, Le Petit-Thevenin J, Bruneau N, Lombardo D, Verine A. In vitro angiogenic effects of pancreatic bile salt-dependent lipase. Arterioscler Thromb Vasc Biol. 2005;25(2):359–64.
Laschke MW, Elitzsch A, Vollmar B, Vajkoczy P, Menger MD. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Hum Reprod. 2006;21(1):262–8.
Bruick RK, McKnight SL. Building better vasculature. Genes Dev. 2001;15(19):2497–502.
Komori M, Tomizawa Y, Takada K, Ozaki M. A single local application of recombinant human basic fibroblast growth factor accelerates initial angiogenesis during wound healing in rabbit ear chamber. Anesth Analg. 2005;100(3):830–4. table of contents.
Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol. 2002;29(6 Suppl 16):10–4.
Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol. 2002;29(6):3–9.
Acknowledgments
The authors thank Dr. Hang Lin, Ms. Xia Wang and Ms. Jin Han from Dai Lab for invaluable comments, and Ms Juan Fan and Mr Xianglin Hou from Dai Lab for their technical assistance. This work was supported by grants from National Natural Science Foundation of China (30688002; 30600304), the Ministry of Science and Technology of China (2006CB943601), Chinese Academy of Sciences (KSCX2-YW-R-133) and K. C. Wang Education Foundation.
Author information
Authors and Affiliations
Corresponding author
Additional information
These authors contributed equally to this work.
Rights and permissions
About this article
Cite this article
Chen, L., He, Z., Chen, B. et al. Loading of VEGF to the heparin cross-linked demineralized bone matrix improves vascularization of the scaffold. J Mater Sci: Mater Med 21, 309–317 (2010). https://doi.org/10.1007/s10856-009-3827-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10856-009-3827-9